These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 35092844)

  • 1. Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.
    Coughlan L; Kremer EJ; Shayakhmetov DM
    Mol Ther; 2022 May; 30(5):1822-1849. PubMed ID: 35092844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral vector vaccines.
    McCann N; O'Connor D; Lambe T; Pollard AJ
    Curr Opin Immunol; 2022 Aug; 77():102210. PubMed ID: 35643023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research and application of the SARS-CoV-2 vaccine based on adenovirus vector technology platform].
    Zhang Y; Yu WZ; Yin ZD; Wang TZ; Sun XD; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jul; 57(7):1082-1095. PubMed ID: 37198717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?
    Doerfler W
    Virus Res; 2021 Sep; 302():198466. PubMed ID: 34087261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights from the Construction of Adenovirus-Based Vaccine Candidates against SARS-CoV-2: Expecting the Unexpected.
    Weklak D; Tisborn J; Mangold MH; Scheu R; Wodrich H; Hagedorn C; Jönsson F; Kreppel F
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19: Prospective Challenges and Potential Vaccines.
    Shahid Nadeem M; Ali A; Al-Ghamdi MA; Depfenhart M; Azam Khan J; Zamzami MA; Nazia Murtaza B; Kazmi I; Ur Rehman M
    Altern Ther Health Med; 2020 Aug; 26(S2):72-78. PubMed ID: 32845250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.
    Sallard E; Zhang W; Aydin M; Schröer K; Ehrhardt A
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice.
    Cao K; Wang X; Peng H; Ding L; Wang X; Hu Y; Dong L; Yang T; Hong X; Xing M; Li D; Zhu C; He X; Zhao C; Zhao P; Zhou D; Zhang X; Xu J
    J Virol; 2022 Feb; 96(4):e0157821. PubMed ID: 34908443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccines: Where Did We Stand at the End of 2023?
    Lundstrom K
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People.
    Garbuglia AR; Minosse C; Del Porto P
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus vector-based vaccine for infectious diseases.
    Sakurai F; Tachibana M; Mizuguchi H
    Drug Metab Pharmacokinet; 2022 Feb; 42():100432. PubMed ID: 34974335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms.
    Aileni M; Rohela GK; Jogam P; Soujanya S; Zhang B
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Vaccines: Adenoviral Vectors.
    Jacob-Dolan C; Barouch DH
    Annu Rev Med; 2022 Jan; 73():41-54. PubMed ID: 34609905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.
    Chavda VP; Bezbaruah R; Athalye M; Parikh PK; Chhipa AS; Patel S; Apostolopoulos V
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of adenovirus vectors and their use as a delivery system for influenza vaccines.
    Vemula SV; Mittal SK
    Expert Opin Biol Ther; 2010 Oct; 10(10):1469-87. PubMed ID: 20822477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.
    Ewer K; Sebastian S; Spencer AJ; Gilbert S; Hill AVS; Lambe T
    Hum Vaccin Immunother; 2017 Dec; 13(12):3020-3032. PubMed ID: 29083948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress and challenge of vaccine development against 2019-novel coronavirus (2019-nCoV)].
    Shi Y; Wang N; Zou QM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Jun; 54(6):614-619. PubMed ID: 32234130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.